Chromogranin A in Neuroendocrine Tumors

Diagnostic Value

• Chromogranin A is elevated in 60% or more of patients with both functioning and non-functioning pancreatic neuroendocrine tumors, making it the best general neuroendocrine serum marker available 1, 2

Prognostic Significance

• Elevated Chromogranin A levels strongly correlate with tumor volume, and levels elevated twice the normal limit or higher are associated with shorter survival times for patients with metastatic NETs (HR, 2.8; 95% CI, 1.9–4.0; P<.001) 1, 3
• Chromogranin A levels appear to be prognostic in patients treated with everolimus 1

Clinical Applications by Tumor Type

• For pheochromocytoma/paraganglioma, Chromogranin A testing is recommended approximately 14 days following surgery and every 3-4 months for 2-3 years thereafter 4
• For appendiceal carcinoid tumors, Chromogranin A is the most useful general marker, with elevated levels associated with recurrence and poorer survival outcomes 5

Important Limitations and False Positives

• Spuriously elevated Chromogranin A levels can occur in patients using proton pump inhibitors, those with renal or liver failure, hypertension, and chronic gastritis 1, 2, 4
• Rising Chromogranin A levels in an asymptomatic patient with stable imaging does not necessarily indicate the need for new therapy 3

Surveillance Recommendations

• Chromogranin A may be used as a tumor marker during surveillance of resected NETs; although not diagnostic, elevated levels have been associated with recurrence 3
• For patients with malignant pheochromocytoma/paraganglioma, SDHB mutation, extra-adrenal primary disease, or pheochromocytoma without relevant preoperative hormone secretion, lifelong follow-up with Chromogranin A monitoring is recommended 4
• Elevated circulating Chromogranin A during follow-up should prompt imaging studies including thorax and abdomen CT and functional imaging 4

Complementary Markers

• 5-Hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, may be considered as a complementary biochemical marker, particularly in patients with metastatic small-intestinal NETs 3
• Chromogranin B may be elevated when Chromogranin A is in the reference range, making it a useful additional marker 5
• Pancreastatin is specifically elevated in metastatic neuroendocrine tumors and not affected by conditions that commonly elevate Chromogranin A 5

Chromogranin A in Neuroendocrine Tumors

Diagnostic Role and Limitations

• The National Comprehensive Cancer Network recommends excluding spurious elevations from proton pump inhibitor use, renal insufficiency, and hepatic insufficiency before interpreting elevated Chromogranin A levels 6, 7

Surveillance and Monitoring

• The European Society for Medical Oncology guidelines recommend measuring Chromogranin A levels every 3-6 months for up to 10 years post-resection for carcinoid tumors with elevated baseline Chromogranin A 8, 9
• The National Comprehensive Cancer Network recommends reevaluating Chromogranin A levels at 3-12 months post-resection, then every 6-12 months thereafter for most other resected neuroendocrine tumors 6, 7
• The European Society for Medical Oncology and the National Comprehensive Cancer Network agree that rising Chromogranin A levels in an asymptomatic patient with stable imaging does not necessarily indicate the need for new therapy 6, 7, 8

Monitoring Treatment Response

• The Annals of Oncology recommends biochemical testing every 3 months, with imaging every 6 months during treatment monitoring 10, 11

Complementary Markers

• The National Comprehensive Cancer Network recommends measuring 5-Hydroxyindoleacetic acid in addition to Chromogranin A for small intestinal carcinoids, particularly those with carcinoid syndrome 6, 12, 7
• Patients must avoid certain foods, substances, and medications that can increase 5-Hydroxyindoleacetic acid levels for 48 hours before and during collection 6, 7

Specific Tumor Type Recommendations

• The National Comprehensive Cancer Network recommends follow-up endoscopies at 6 and 12 months after primary therapy for rectal carcinoids 1-2 cm in size 6

Algorithmic Approach to Chromogranin A Interpretation

• The National Comprehensive Cancer Network and the European Society for Medical Oncology recommend confirming patient is off proton pump inhibitors for at least 2 weeks and has no renal or hepatic insufficiency before interpreting elevated Chromogranin A levels 6, 8, 9

Chromogranin A in Neuroendocrine Tumors

Diagnostic and Prognostic Value

• For bronchial typical carcinoids, increased plasma CgA levels are characteristic findings, according to the European Society for Medical Oncology 13
• Both typical and atypical carcinoids express neuroendocrine markers by immunohistochemistry, including chromogranin A, synaptophysin, and neuron-specific enolase, as recommended by the College of American Pathologists 13
• Large-cell carcinoma and small-cell lung carcinoma weakly or rarely express these markers, making CgA less useful for undifferentiated tumors, as stated by the National Comprehensive Cancer Network 13
• For post-resection monitoring of carcinoid tumors with elevated baseline CgA, measure CgA every 3-6 months for up to 10 years post-resection, and perform CT or MRI imaging once yearly, as suggested by the European Neuroendocrine Tumor Society 13
• Measure CgA every 3 months during cytotoxic or biological treatment, and perform imaging evaluation at least every 6 months for metastatic or recurrent disease, as recommended by the American Society of Clinical Oncology 13

Treatment and Management

• For low-proliferating tumors with severe clinical symptoms, somatostatin analogs and alpha-interferons are treatment options, according to the European Society for Medical Oncology 13
• The use of somatostatin analogs remains controversial in non-functional tumors, as stated by the National Institute of Health 13
• Tumor-targeted radioactive treatment is an option for tumors with high somatostatin receptor content, as recommended by the Society of Nuclear Medicine and Molecular Imaging 13